Asterias Biotherapeutics, Inc. - FORM 10-K - EX-32 - EXHIBIT 32 - March 29, 2016

Attached files

file filename
EX-31 - EXHIBIT 31 - Asterias Biotherapeutics, Inc.ex31.htm
EX-23.1 - EXHIBIT 23.1 - Asterias Biotherapeutics, Inc.ex23_1.htm
EX-23.2 - EXHIBIT 23.2 - Asterias Biotherapeutics, Inc.ex23_2.htm
EX-10.31 - EXHIBIT 10.31 - Asterias Biotherapeutics, Inc.ex10_31.htm
EX-10.33 - EXHIBIT 10.33 - Asterias Biotherapeutics, Inc.ex10_33.htm
EX-10.35 - EXHIBIT 10.35 - Asterias Biotherapeutics, Inc.ex10_35.htm
EX-10.34 - EXHIBIT 10.34 - Asterias Biotherapeutics, Inc.ex10_34.htm
EX-10.32 - EXHIBIT 10.32 - Asterias Biotherapeutics, Inc.ex10_32.htm
10-K - ASTERIAS BIOTHERAPEUTICS, INC 10-K 12-31-2015 - Asterias Biotherapeutics, Inc.form10k.htm
Exhibit 32

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Asterias Biotherapeutics, Inc. (the “Company”) for the year ended December 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we Stephen L. Cartt, Chief Executive Officer, and Russell L. Skibsted, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
Date: March 29, 2016
  
     
 
/s/ Stephen L. Cartt
  
 
Stephen L. Cartt
  
 
Principal Executive Officer
  
     
 
/s/ Russell L. Skibsted
  
 
Russell L. Skibsted
  
 
Principal Financial Officer
  
 
 

Asterias Biotherapeutics, Inc. Reports